Phathom Pharmaceuticals, Inc. current report, 27 September 2022

Full document

Filing Overview

Phathom Pharmaceuticals, Inc. filed a Form 8-K reporting entry into the Second Loan Amendment on September 27, 2022. The company is a Delaware corporation headquartered in Florham Park, New Jersey, and its common stock trades on Nasdaq under the symbol PHAT.

Material Financing Amendment

  • The amendment modifies the company’s Loan and Security Agreement dated September 17, 2021, with Hercules Capital, Inc. serving as administrative and collateral agent.
  • The availability period for a second tranche of $50 million was extended from December 15, 2022, to February 15, 2023, subject to specified conditions.
  • If the PDUFA target action date for the company’s pending New Drug Application is extended beyond the then-current date, the availability period may instead extend to May 15, 2023.
  • The commencement date for the revenue covenant was moved from May 15, 2023, to November 15, 2023. The covenant requires the company to achieve a specified level of trailing three-month net product revenue from vonoprazan and products containing vonoprazan.

Financial Metrics and Reporting Period

This 8-K does not report quarterly revenue, profit, cash flow, margins, debt balances, liquidity balances, or other operating metrics. The filing date is September 27, 2022; the amendment is expected to be filed as an exhibit to the company’s Form 10-Q for the quarter ended September 30, 2022.

Outlook, Risks, and Unusual Items

  • The financing amendment appears intended to provide additional timing flexibility around the regulatory review of the pending New Drug Application.
  • Access to the $50 million tranche remains subject to specified conditions and is not presented as an unconditional funding commitment.
  • The filing does not provide the PDUFA target action date, identify all conditions to borrowing, or quantify the required revenue-covenant threshold.
  • The filing text does not provide additional management commentary, financial guidance, contingencies, or risk-factor updates.

Investor Verification Items

  • Review the full Second Loan Amendment when filed as an exhibit to the Form 10-Q.
  • Verify the applicable PDUFA target action date and whether any extension affects the potential February 15, 2023 or May 15, 2023 funding deadline.
  • Confirm the conditions for accessing the $50 million tranche and the related interest, maturity, collateral, and other loan terms.
  • Confirm the specific revenue threshold and other requirements under the delayed covenant.